drugset / Trial / NCT02183077

Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects

NCT02183077

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to gain information on the percutaneous absorption of meloxicam after administration of a topical gel over 7 days.

Timeline

Start
1998-09
Primary completion
1998-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg Topical
Subject Meloxicam Small molecule 15 mg Topical

Indications

No indication recorded.